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Summary Our understanding of asthma severity was advanced by the identification
of biomarkers which account for differences in lung function impairment. We tried to
examine the effects of corticosteroid treatment on known correlates of asthma
severity including peripheral eosinophil counts, total IgE, IL-5, and eotaxin levels in
plasma.
We compared these biomarkers among groups of stable asthmatics categorized by
the dose of corticosteroid (N: steroid-free, n ¼ 25; L: low-dose inhaled, n ¼ 27; MH:
medium or high-dose inhaled, n ¼ 19; O: inhaled plus oral, n ¼ 8). Next we
compared these markers and peak expiratory flow rate (PEFR) in unstable asthmatics
before and after treatment with steroids (n ¼ 22).
Eotaxin levels in the O group were higher than those in the N and MH groups
(Po0:05). Logistic regression analysis demonstrated that plasma eotaxin level was
correlated with the severity of asthma defined by treatment intensity (P ¼ 0:01) and
% FEV1 (P ¼ 0:04) while the other markers were not. Eotaxin levels did not change
after steroid treatment in unstable patients, whereas eosinophil counts decreased in
parallel with PEFR.
Among biomarkers of asthma severity studied, plasma eotaxin level was not
significantly affected by corticosteroid treatment, and was associated with the
severity even in the presence of steroid therapy.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Bronchial asthma is a chronic disease characterized
by eosinophilic inflammation of the airways. Since
the introduction of inhaled steroid therapy, asthma
treatment has dramatically improved and most
asthmatics have been managed in outpatient clinics
without hospital admission. The concept of asthma
severity has also changed and the required dose of
inhaled steroid to control clinical symptoms and
maintain pulmonary function has been regarded as
one of the important indices of disease severity.1
Inhaled corticosteroid therapy has been thought to
cause few adverse effects, but there is accumulat-
ing evidence that long-term and high-dose therapy
may lead to unfavorable effects including cataracts
and osteoporosis.2,3 It is, therefore, important to
determine the optimal dose of inhaled steroid to
maintain long-term remission in asthma patients. In
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addition, some severe asthmatics do not respond
well to inhaled steroids and require continuous
systemic steroid therapy. It is thus meaningful to
associate predictive biomarkers with asthma sever-
ity as judged by intensity of treatment.
Previous reports demonstrated that various para-
meters such as peripheral eosinophil counts,4,5 IgE
levels,6,7 IL-5 levels,8,9 and %FEV1 are useful markers
for monitoring the activity or predicting the severity
of asthma. However, these parameters may be
modified by treatment with corticosteroids, and
their usefulness has not been fully analyzed in the
presence of steroid therapy although the majority of
asthmatics are now being treated with steroids.
Eotaxin is a CC chemokine that recruits eosinophils
by activating the CCR3 receptor.10 The expression of
eotaxin was found to be increased in the airways of
asthmatics, and the elevation of eotaxin levels was
proportional to eosinophil infiltration and bronchial
hyperreactivity.11,12 We have recently reported that
plasma eotaxin levels inversely correlate with lung
function in asthmatics not treated with steroids.13 In
addition, plasma eotaxin levels were reported to
increase in patients with acute asthma compared
with those in stable patients.14 It was also suggested
that plasma eotaxin level tended to be higher in
severe asthmatics than in mild patients when they
were stratified by the response to emergency
treatment, the presence of systemic steroid on
presentation, or the requirement of hospital admis-
sion.14 Based on these observations we hypothesized
that plasma eotaxin level can be a biomarker of
asthma severity regardless of steroid treatment. In
order to test this hypothesis, we compared plasma
eotaxin levels, peripheral eosinophil counts, IL-5
levels, IgE levels, and %FEV1 among patients with
stable asthma of different severity based on the
intensity of steroid treatment. Next we compared
these markers in symptomatic asthmatics before and
after treatment with steroids.
Materials and methods
Subjects
One hundred and one asthma patients visiting the
outpatient clinic at Keio University Hospital be-
tween August and September, 1998 (79 stable
patients) and between April and July, 2000 (22
unstable patients) were enrolled. All patients met
the diagnostic criteria for asthma in the Global
Initiative for Asthma,1 and had been diagnosed with
asthma by a physician at least 1 year before
enrollment in the present study.
In order to investigate the differences in bio-
markers in stable asthmatics of different severity,
consecutive patients who met the following criteria
were designated as stable patients; (1) medication
was unchanged at least for 3 months, and (2) step-
up of treatment was judged unnecessary from their
clinical symptoms and pulmonary function, i.e.,
they had minimal chronic symptoms including
nocturnal symptoms, minimal exacerbations, no
emergency visits, minimal use of as-needed
b2-agonist, no limitations on activities, and FEV1
greater than 80% of the personal best.1 The
enrolled asthma patients were divided into four
groups according to the maintenance doses of
corticosteroids; (1) N group, n ¼ 25: not treated
with steroids, (2) L group, n ¼ 27: treated with a
low dose of inhaled beclomethasone dipropionate
(BDP) (p500 mg/day),1 (3) MH group, n ¼ 19:
treated with a medium or high dose of inhaled
BDP (4500 mg/day), (4) O group, n ¼ 8: treated
with both a medium or high dose of inhaled BDP and
oral daily prednisolone (PSL). BDP was inhaled with
a spacer in all patients. Stable asthmatics were also
divided into three groups by %FEV1; (1) mild group,
n ¼ 45: %FEV1X80%, (2) moderate group, n ¼ 19:
60%p%FEV1o80%, (3) severe group, n ¼ 13:
%FEV1o60%. In two patients baseline pulmonary
function test was not available and they were
judged as stable by their clinical symptoms.
To elucidate the effects of steroids on clinical
parameters during an acute exacerbation of asth-
ma, consecutive patients who met the following
criteria were defined as unstable; (1) step-up or
additional treatment was necessary based on their
clinical symptoms and pulmonary function, and (2)
medication was unchanged for at least 3 months
prior to initiating additional therapy with steroids.
There were no patients who required admission or
intravenous steroid therapy during the study
period. No patient overlapped between the stable
and unstable groups. The unstable patients were
categorized into three groups in terms of steroid
therapy; (1) N-US [fluticasone propionate (FP)],
n ¼ 9: unstable asthmatics who had not been
treated with steroids, and initiation of inhaled
steroid therapy was judged necessary. These
patients were treated with 200 mg FP bid for 4
weeks with a disk inhaler. (2) N-US (PSL), n ¼ 6:
unstable asthmatics who had not been treated with
steroids, and oral steroid therapy was considered
necessary due to their severe symptoms. These
patients were treated with 30mg PSL/day orally for
1 week. (3) IS-US (PSL), n ¼ 7: unstable asthmatics
who had been treated with inhaled steroids (FP:
200–800 mg/day), and step-up or additional steroid
therapy was considered to be necessary. These
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patients were treated with 30mg PSL/day orally for
1 week regardless of the severity of the exacerba-
tion. No other medication was changed during
treatment with steroid. The reason for the change
in inhaled steroid from BDP to FP is that FP became
available in our hospital in April 1999.
Forty-one healthy subjects without asthmatic
manifestations were selected as controls (CTL).
Their age and gender were 3073 (median: 31,
range: 24–34) years old and male/female (M/F):
20/21, respectively. Eight subjects were current
smokers, three were ex-smokers (who had quit
smoking for at least 6 months), and thirty had never
smoked. Atopic status was not considered as the
inclusion criteria for the CTL. Prior informed
consent was obtained from all patients and healthy
controls.
Study design
A cross-sectional study was performed to compare
plasma eotaxin and IL-5 levels, serum IgE levels,
and peripheral eosinophil counts in stable asth-
matics stratified according to their treatment. An
open intervention study was also performed to
investigate the effects of steroid treatment on the
levels of these biomarkers in unstable asthmatics.
Determination of biochemical and functional
parameters
Plasma eotaxin levels were determined by a
sandwich enzyme-linked immunosorbent assay (ELI-
SA) as previously reported.13–15 Plasma IL-5 levels
were measured using an ELISA kit purchased from
R&D Systems (Minneapolis, MN, USA). Serum IgE
level was measured by a chemiluminescent enzyme
immunoassay (LUMIWARD, Shionogi, Osaka, Japan).
Normal range of serum IgE level was less than
250 IU/ml in this assay. Pulmonary function tests
were performed using a spirometer (rolling-seal
spirometer, Chest, Tokyo, Japan) when the patients
were judged to be clinically stable (77 stable
patients) or just after treatment with steroids (22
unstable patients). Peak expiratory flow rate
(PEFR) measured in the morning with a peak flow
meter (Personal Best, Healthscan Products Inc.,
Cedar Grove, NJ, USA) was compared before and
after steroid therapy with FP (4 weeks) or PSL
(1 week) in unstable asthmatics.
Statistical analysis
Data were expressed as mean7SD and median
values. Kruskal–Wallis rank test was used to
compare the values among the N, L, MH, and O
groups and Dunnett test was applied as a post-hoc
test. Mann–Whitney’s U-test was performed to
compare the values between two unpaired groups.
Wilcoxon signed-ranks test was used to compare
values between two paired groups. Multiple logistic
regression analysis was performed to examine the
contribution of factors to asthma severity. A
P-value of less than 0.05 was considered statisti-
cally significant.
Results
Clinical profiles of asthma patients
The clinical characteristics of stable and unstable
asthmatics in each group are presented in Table 1.
All patients were treated with inhaled or oral
b-agonists. Some asthmatics were treated with
theophylline and/or a cysteinyl leukotriene 1
receptor antagonist. There was no statistically
significant difference in %FEV1 among the N, L,
MH, and O groups or between the N-US and IS-US
groups.
Plasma eotaxin level and peripheral
eosinophil count in steroid-free and steroid-
treated asthmatics
Plasma eotaxin levels were higher in asthmatics
treated with inhaled steroids (STEROID group: n ¼
61; patients in the L, MH, O, and IS-US groups) than
in asthmatics who had not required continuous
steroid therapy (NONE group: n ¼ 40; patients in
the N and N-US groups) (Po0:05; 2677193, 218 vs.
1907153, 165 pg/ml, respectively) (Fig. 1a). There
was no significant difference in eosinophil count
between the STEROID and NONE groups (4257301,
347 vs. 4377348, 367 ml, respectively) (Fig. 1b).
Neither was there a difference in IgE level between
the two groups (P ¼ 0:15; 75071160, 380 vs.
66071380, 180 IU/ml, respectively). In contrast
to the behavior of eotaxin, plasma IL-5 level in the
STEROID group was lower than that in the NONE
group (P ¼ 0:046; 1.273.1, 0 vs. 2.373.2, 0 pg/
ml), although the mean level was below the
detection limit in both groups. In the N-US and IS-
US groups, only the values before initiating steroid
therapy were included in this analysis.
When the STEROID and NONE groups were
combined, eotaxin levels were significantly higher
in the asthmatics group (n ¼ 101) than in the CTL
group (Po0:0001; 2377181, 190 vs. 1217110,
108pg/ml, respectively). IgE levels were also higher
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in the asthmatics group than in the CTL group
(Po0:01; 72071240, 330 vs. 2007190, 130 IU/ml,
respectively). Peripheral eosinophil counts and IL-5
levels were not available in the CTL group. In the
asthmatics group (n ¼ 101), IL-5 levels were sig-
nificantly correlated with eosinophil counts
(r ¼ 0:21; P ¼ 0:03) while neither eotaxin nor IgE
was correlated with them.
Relation of biomarkers to intensity of asthma
treatment
Plasma eotaxin levels in the N, L, MH, O, N-US, and
IS-US groups were 1817164 (157), 2597216 (177),
1967145 (190), 3907171 (421), 2067136 (177),
and 3517171 (344) pg/ml, respectively. Eotaxin
levels were increased in the O group compared to
the N and MH groups (Po0:05; Fig. 2a). Eotaxin
levels in the IS-US group were higher than in the N-
US and MH groups (wzPo0:05; Fig. 2a).
Peripheral eosinophil counts in the N, L, MH, O,
N-US, and IS-US groups were 3787236 (322),
3917253 (303), 5847350 (551), 125771 (106),
5357474 (403), and 4677219 (451)ml1, respec-
tively. Eosinophil counts were increased in the MH
group compared to that in the N, L, and O groups
(Po0:05; 0.05, and 0.01, respectively, Fig. 2b).
There was no significant difference in IgE levels
among the N, L, MH, and O groups or between the
N-US and IS-US groups (Table 1). IL-5 levels were
higher in the N-US group than in the N group
[3.773.3 (2.3) vs. 1.470.6 (0) pg/ml, Po0:01].
Biomarkers and FEV1
Plasma eotaxin levels in the mild, moderate, and
severe groups classified by %FEV1 were 230726
(201), 205746 (130), and 298761 (268), respec-
tively. The difference in eotaxin levels among the
groups was not statistically significant. Neither was
there a significant difference in plasma IL-5 levels,
serum IgE levels, or peripheral eosinophil counts
among the groups.
Logistic regression analysis of factors related
to severity of asthma
Factors independently correlated with the severity
of asthma were evaluated by multiple logistic
regression analyses in stable asthmatics (n ¼ 79)
(Table 2). Severe asthma was defined as belonging
to the O group or % FEV1o60 in these analyses.
Since the negative effect of oral steroids on
peripheral eosinophil counts and IL-5 levels were
apparent, these factors were excluded from the
analysis of the O group. Plasma eotaxin level and
age were correlated with the severity judged by
treatment intensity. These two factors were also
correlated with the severity evaluated by pulmon-
ary function. The other factors did not significantly
relate to the severity defined by these two criteria.
There was no correlation between age and plasma
eotaxin levels in asthmatics (r ¼ 0:10; P ¼ 0:37) or
in control subjects (r ¼ 0:03; P ¼ 0:84) by a simple
linear regression analysis.
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Table 1 Clinical profiles of asthmatics.
Group n Gender Age Duration Smoking Inhaled steroid Oral PSL %FEV1 Total IgE
(M/F) (years) (C/E/NS) (mg/day) (mg/day) (IU/ml)
N 25 16/9 51717 14718 6/6/13 0 0 87720 72071650
(89) (173)
L 27 12/15 51716 14710 3/3/21 BDP 0 83715 79071290
2907100 (83) (375)
MH 19 12/7 53716 13715 3/7/9 BDP 0 84721 77071220
10707490 (89) (369)
O 8 3/5 65710 16714 2/2/4 BDP 7.273.1 68729 67071050
16007430 (61) (380)
N-US 15 10/5 45716 8710 4/2/9 0 0 86716 5607750
(86) (195)
IS-US 7 3/4 48711 19719 1/1/5 FP 0 80721 6307620
4007200 (81) (405)
M: male; F: female; C: current smoker; E: ex-smoker; NS: nonsmoker; PSL: prednisolone; N: clinically stable asthmatics not
treated with steroid; L: those with low-dose inhaled steroid; MH: those with medium or high-dose inhaled steroid; O: those with
medium or high-dose inhaled steroid and oral PSL; N-US: unstable asthmatics not treated with steroid; IS-US: those with inhaled
steroid; BDP: beclomethasone dipropionate; FP: fluticasone propionate.
Parentheses represent median values of %FEV1 and total IgE level.
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Figure 2 Plasma eotaxin levels (a) and peripheral
eosinophil counts (b) in asthmatics. N: stable patients
not treated with steroid, L: stable patients treated with
low-dose inhaled steroid, MH: stable patients treated
with medium or high-dose inhaled steroid, O: stable
patients treated with inhaled and oral steroids, N-US:
unstable patients not treated with steroid, IS-US:
unstable patients treated with inhaled steroids. Horizon-
tal lines represent median values. Eotaxin level was
higher in the O group than in the N and MH groups (a:
Po0:05). wPo0:05 vs. the N-US group, zPo0:05 vs. the
MH group (a). Eosinophil count was higher in the
MH group than in the N, L (Po0:05), and O (Po0:01)
groups (b).
Table 2 Logistic regression analysis of factors related to severity of asthma.
O group %FEVo60
w2 P OR (95%CI) w2 P OR (95%CI)
Age (10 years) 6.3 0.01 4.7 (1.4–15.8) 8.1 0.01 2.8 (1.4–5.5)
Smoking history 2.3 0.13 5.3 (0.6–46.1) 0.01 0.94 0.9 (0.2–4.1)
Eotaxin (100 pg/ml) 7.3 0.01 2.5 (1.3–4.9) 4.0 0.04 1.5 (1.0–2.3)
Eosinophil (100/ml) F F F 0.9 0.35 1.1 (0.9–1.5)
IgE (100 IU/ml) 2.6 0.10 1.1 (1.0-1.2) 0.02 0.89 1.0 (0.9–1.1)
IL-5 (1 pg/ml) F F F 0.4 0.54 1.1 (0.9–1.3)
O group: asthmatics treated with inhaled and oral steroids; OR: odds ratio; CI: confidence interval.
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Figure 1 Plasma eotaxin levels (a) and peripheral
eosinophil counts (b) in asthmatics treated with (STER-
OID: n ¼ 61) or without steroids (NONE: n ¼ 40). Hor-
izontal lines represent median values. Po0:05;
compared with NONE.
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Effects of treatment with steroids on
biomarker levels in unstable asthmatics
Biomarker levels in stable and unstable asthmatics
are shown in Table 3. IL-5 level was significantly
higher in unstable asthmatics than in stable
patients. Eotaxin level and eosinophil counts were
not significantly different between the groups.
Changes in biomarker levels and PEFR before and
after treatment with FP or PSL in unstable
asthmatics are presented in Table 4. Eotaxin levels
did not change after treatment with inhaled FP in
the N-US (FP) group, or after treatment with oral
PSL in the N-US (PSL) and the IS-US (PSL) groups.
PEFR significantly increased after treatment with
FP or PSL in the N-US (FP), N-US (PSL), and IS-US
(PSL) groups, despite the behavior of eotaxin. In
contrast, peripheral eosinophil counts tended to
decrease after treatment with FP in the N-US (FP)
group (P ¼ 0:07) and significantly decreased after
treatment with PSL in the N-US (PSL) and the IS-US
(PSL) groups (P ¼ 0:03 and 0.02, respectively)
(Table 4). There was no significant change in IgE
levels before and after the treatment in any of the
groups studied. IL-5 levels were decreased after
steroid treatment in the N-US (PSL) group. The
ratio of PEFR after steroid treatment to that before
the treatment was significantly correlated with
plasma eotaxin levels before the treatment in N-
US(FP) and IS-US(PSL) groups (Fig. 3). In N-US(PSL)
group there was an exceptional patient with low
eotaxin level and high PEFR ratio (shown as a solid
square). When this patient was excluded, there
would be a good correlation in this group as well
(r ¼ 0:92; P ¼ 0:02).
Discussion
The present study demonstrated that plasma
eotaxin levels were highest in asthmatics who
required both inhaled and systemic steroids.
Plasma eotaxin levels were also significantly higher
in asthmatics treated with steroids than in steroid-
free asthmatics. Logistic regression analysis sug-
gested that among biomarkers studied only plasma
eotaxin levels were related to the degree of airflow
obstruction as well as treatment intensity. Treat-
ment of unstable asthmatics with oral or inhaled
corticosteroids did not significantly affect plasma
eotaxin levels. These observations imply that
plasma eotaxin levels are relatively resistant to
corticosteroid treatment and is a better marker of
asthma severity in steroid-treated asthmatics than
biomarkers such as eosinophil counts or IL-5 levels
that are affected by this treatment.
In vitro studies confirmed that corticosteroids
decrease cytokine-induced eotaxin expression in
human epithelial and mononuclear cells in a
concentration-dependent manner.15,16 The present
study, however, demonstrated that the systemic
expression of eotaxin in vivo is not significantly
decreased by clinical doses of inhaled or oral
steroids (Table 4). These discrepancies may be
accounted for by the different environment be-
tween in vitro and in vivo situations, i.e., other
unspecified confounding factors augmenting eotax-
in expression or interfering with steroid effects
may exist in vivo. Plasma eotaxin levels in acute
asthma treated with oral corticosteroids also
tended to be higher than those not treated with
them in a previous study.14 It is unlikely that
systemic steroids increase plasma eotaxin levels
partly because plasma eotaxin levels did not
significantly change after treatment with oral PSL
in healthy volunteers (data not shown).
Peripheral eosinophil counts were correlated
with treatment intensity only in the absence of
systemic steroids. Correlation between eosinophil
counts and severity of asthma was previously
demonstrated in asthmatics not treated with
steroids.4 Plasma eotaxin levels tended to increase
in asthmatics with acute exacerbations (Fig. 2),
which is consistent with the previous observation in
acute asthma.14 However, eotaxin levels did not
parallel the improvement in pulmonary function
after treatment with steroids, whereas peripheral
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Table 3 Biomarker levels in stable and unstable asthmatics.
n IL-5 Eotaxin Eosinophil count
(pg/ml) (pg/ml) (ml1)
Stable asthmatics 79 1.2673.05 2327188 4067289
(0) (179) (326)
Unstable asthmatics 22 2.9173.33 2527159 5137406
(1.61*) (216) (417)
*Po0:01: Parentheses represent median values.
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eosinophil counts were closely related to the
improvement in pulmonary function after initiating
steroid therapy. These results also correspond to
the previous finding that eotaxin levels were
elevated a week after the onset of symptoms of
an asthma exacerbation,14 suggesting that the
elevated eotaxin levels during an exacerbation
continue for at least several days.
In addition, there was a significant correlation
between the pretreatment levels of plasma eotaxin
and the extent of functional improvement after
steroid treatment in unstable asthmatics (Fig. 3).
These results suggest that plasma eotaxin level is a
marker of disease activity and/or treatment re-
sponse to steroids in unstable asthma. Taken
together, plasma eotaxin levels may reflect acute
exacerbations of asthma as well as baseline
severity even in the presence of steroid treatment,
while peripheral eosinophil counts are promptly
suppressed by treatment with steroid. However,
there was no significant difference in eotaxin levels
between all stable and unstable asthmatics (Table
3). These observations may be attributable to the
difference in the baseline severity between the
stable and unstable patients (Table 1).
A recent study demonstrated that low-dose BDP
(336 mg/day) significantly improved lung function of
mild-to-moderate asthmatics in the absence of a
reduction in clinical markers for eosinophilic
inflammation.17 Another study also suggested that
eosinophil counts and eosinophil cationic protein
levels were increased in induced sputum of severe
asthmatics even in the presence of high-dose
inhaled or oral steroids.18 These observations are
not inconsistent with our finding that eosinophil-
related inflammation, which was monitored by
plasma eotaxin levels, peripheral eosinophil
counts, and plasma IL-5 levels in the present study,
was not always diminished by inhaled or oral
corticosteroid therapy even in asthmatics with
stable clinical symptoms.
Plasma IL-5 levels were higher in asthmatics with
acute exacerbations than those in stable asth-
matics (Table 3). However, IL-5 levels during acute
exacerbations decreased after treatment with oral
steroids in patients who had not been treated with
steroids (N-US group) (Table 4). Plasma IL-5 levels
were also lower in asthmatics treated with steroids
than those in steroid-free patients. These observa-
tions imply that plasma IL-5 levels may parallel the
disease activity but are affected by treatment with
steroids, as reported in previous studies.8,19 It is
interesting that plasma eotaxin and IL-5 levels were
differentially regulated, and IL-5, but not eotaxin,
was correlated with eosinophil counts in asth-
matics, although both eotaxin and IL-5 are thought
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to be paramount in promoting eosinophilic inflam-
mation in allergic diseases.20 Correlation between
serum IgE levels and asthma severity was mainly
demonstrated in children with asthma not treated
with steroids.6,7 The effects of steroids on serum
IgE levels are influenced by the route of adminis-
tration, doses of corticosteroids, and duration of
treatment and the interpretation of serum IgE
levels of asthmatics is controversial in the presence
of steroid therapy.21–23 The present study found
that serum IgE levels were not related to either
disease severity, activity, or treatment response to
steroids in an asthmatic population.
Asthma severity is predicted by biomarkers such
as eosinophil counts and IgE levels but disease
treatment may effect the levels of these markers.
Interpretation of plasma eotaxin level in the
assessment of asthma severity is not always
easy, because correlation between eotaxin level
and asthma severity was not perfect, e.g., there
was no significant difference in eotaxin level
among the N, L, and MH groups. Our findings,
however, demonstrate that among biomarkers
which have a predictive value of disease severity,
plasma eotaxin level is less effected by treatment
with corticosteroids and provides more information
about asthma severity that was not available with
the other biomarkers after initiation of steroid
treatment.
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